The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.
An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation in patients treated for early severe systemic sclerosis, providing evidence of sustained positive clinical outcomes and long-term safety for the rare autoimmune disease.
The FDA published new guidance establishing an approval framework for personalized gene editing treatments that could benefit different patient subsets with the same disease, creating a 'plug and play' pathway to accelerate individualized therapies.
Katherine Screws, a Phoenix woman whose small intestine was destroyed in a car crash, waited three years for an intestine transplant while dependent on IV nutrition. She was among just 88 people in the U.S. to receive an intestine transplant last year, illustrating the challenges and complexity of the organ transplant system for rare procedures.
The U.S. Food and Drug Administration is initiating a top-to-bottom review of its rare disease drug development and approval framework, aiming to standardize its approach to scientific evidence and prioritize consistency over flexibility. The new framework seeks to reduce uncertainty for investors and bring rare disease therapies to patients faster.
A man in Arizona died from pneumonic plague last year after having contact with sick cats, according to a recently published report. Pneumonic plague cases are extremely rare in the United States, though plague cases do occasionally occur.
Endeavor BioMedicines announced that its WHISTLE-PF phase 2b trial of taladegib met its primary endpoint, demonstrating statistically significant improvement in lung function (ppFVC) compared to placebo in patients with IPF. The company claims the drug has potential to reverse disease course, unlike current therapies that only slow progression.
Epicrispr Biotechnologies presented encouraging updated findings from testing of its epigenetic editing treatment for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disease. The data builds the case for the company's therapeutic approach to treating the condition.
An investigational drug, z-basivarsen, demonstrated sustained improvements in myotonia, motor function, and strength in patients with myotonic dystrophy type 1, according to analysis from the ACHIEVE trial. The findings suggest potential therapeutic benefits for this genetic neuromuscular disorder.
Kyverna Therapeutics released one-year follow-up data showing patients with stiff person syndrome remained off other therapies after treatment with its CAR-T cell therapy miv-cel. The company plans to file for FDA priority review this year, which would make it the first cell therapy approved for an autoimmune disease.
The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending Zeydovio (glepaglutide) for marketing authorization in treating short-bowel syndrome. The GLP-2 analog is developed by Zealand Pharma A/S.
The FDA granted full approval to Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome type A, marking the first-ever approved treatment for the ultra-rare, fatal neurodegenerative disease. The approval comes after a previous regulatory rejection and represents a significant milestone for patients with this devastating condition.
BrainChild Bio, spun out of Seattle Children's Hospital, secured $116 million in series A funding to advance its lead CAR-T therapy BCB-276 into pivotal trials for diffuse intrinsic pontine glioma, a rare and fatal brain tumor affecting approximately 300 U.S. children annually.
The U.S. Food and Drug Administration approved Mimrylo (rusfertide), developed by Takeda Pharmaceutical and Protagonist Therapeutics, as the first drug of its kind to treat polycythemia vera, a rare blood disorder that causes overproduction of red blood cells.
PTC Therapeutics won the bankruptcy auction for Sangamo Therapeutics' gene therapy assets with a $211 million bid. Sangamo filed for Chapter 11 bankruptcy in June after failing to find strategic alternatives.
Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.
Silence Therapeutics announced that its Phase 2 SANRECO trial of divesiran met its primary endpoint in patients with polycythemia vera, a rare blood cancer, with data showing the treatment stabilized red blood cell levels and reduced phlebotomies to 0.2 per patient over 36 weeks. The company's stock rallied significantly on the news.
Intellia Therapeutics announced second quarter 2026 financial results alongside positive Phase 3 clinical data for lonvo-z in hereditary angioedema (HAE), with FDA biologics license application acceptance anticipated in late 2026 and U.S. commercial launch planned for first half of 2027.
Tarsus Pharmaceuticals agreed to acquire privately-held Alkeus Pharmaceuticals for $450 million upfront and up to $800 million total, gaining gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease. The rare genetic eye condition affects over 36,000 people in the U.S. and currently has no FDA-approved treatment, with pivotal trial data expected in late 2029.
Merck's anti-TL1A antibody from its 2023 Prometheus Biosciences acquisition delivered positive mid-stage results in hidradenitis suppurativa but failed to meet endpoints in a rare lung disease trial. The company disclosed the mixed Phase 2 results alongside its second-quarter earnings.
Britain's medicines regulator has approved Cytokinetics' drug for a rare heart condition, with the National Institute for Health and Care Excellence (NICE) recommending it for NHS reimbursement, making it accessible to approximately 6,600 patients in the UK.
Researchers have developed a new interventional treatment for hepatic myelopathy, a rare neurological complication of chronic liver disease that previously could only be cured through liver transplantation.
AstraZeneca announced Monday that its rare disease drug Ultomiris failed a late-stage trial for blood vessel complications following stem cell transplants, while a separate trial of its Claudin 18.2-targeting antibody-drug conjugate in stomach cancer succeeded. The Ultomiris setback adds to concerns about the drugmaker's pipeline following a series of setbacks this year.
Catherine L'Estrange from North Acton became the first patient in the UK and second in the world to receive groundbreaking gene therapy for Bardet-Biedl syndrome, a rare condition that progressively causes blindness in children. The treatment, performed at St Helier Hospital in March, involves injecting healthy copies of a gene directly into the eye.
Three major research institutions announced the creation of the Center for Therapeutic Genetics, a nonprofit collaboration aimed at developing standardized genetic medicines, including base and prime editing, for rare and ultra-rare diseases that currently lack treatments.
Two patients with SCN2A-related developmental epileptic encephalopathy experienced reductions in seizure frequency after receiving individualized allele-selective antisense oligonucleotides. The treatments were well tolerated, with no ASO-related serious adverse events reported in two parallel single-patient studies published in Nature Medicine.
A Northern California resident was hospitalized this spring after being confirmed as the fourth-ever person diagnosed with an extremely rare tick-borne disease caused by Rickettsia lanei bacteria, which produces symptoms similar to Rocky Mountain spotted fever. State health officials are warning residents to take precautions against ticks following the diagnosis.
Michael Larkin of Shirley, Long Island, survived New York's first confirmed case of Bourbon virus after being bitten by ticks while landscaping in May 2021. The rare tick-borne illness caused severe symptoms including high fevers, headaches, and rash, requiring a five-day hospitalization.